Intracellular Th (ITCI) - Stock Price & Dividends

Intra-Cellular Therapies, Inc., traded on the NASDAQ under the symbol ITCI, is a biopharmaceutical company based in the United States. The company's focus is on the discovery, clinical development, and commercialization of small molecule drugs that target intracellular signaling mechanisms in the central nervous system (CNS), primarily to address medical needs related to neuropsychiatric and neurological disorders.

One of Intra-Cellular Therapies' key offerings is CAPLYTA, a treatment designed for adults dealing with schizophrenia and bipolar depression. The company is also actively engaged in trials for Lumateperone, a drug intended to treat various depressive disorders and other neuropsychiatric indications, currently in Phase 3 clinical testing.

Furthermore, Intra-Cellular Therapies is working on Lenrispodun (ITI-214), with a focus on addressing Parkinson's disease, CNS disorders, and related conditions. They are also developing ITI-1284 for neuropsychiatric disorders and behavioral disturbances in dementia, along with ITI-333, which aims to tackle substance use disorders, pain management, and psychiatric comorbidities like depression, anxiety, and sleep disorders.

Founded in 2002 and headquartered in New York, New York, Intra-Cellular Therapies, Inc. has a clear mission to advance the field of pharmacology in the treatment of CNS-related conditions. To learn more about their work, you can visit their website at https://www.intracellulartherapies.com.